Brentuximab vedotin
Orphan Drug Cold Chain RequiredFDA Approved
Contents
Description
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The ADC is composed of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE).
Indications & Therapeutic Use
CD30+ cutaneous T-cell lymphoma
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Brentuximab vedotin — GNH India
5 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Brentuximab vedotin products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Brentuximab vedotin
| Generic Name | Brentuximab vedotin |
| Brands | 1 brand available |
| Active Ingredient | Brentuximab vedotin |
| Drug Class | CD30+ cutaneous T-cell lymphoma |
| Manufacturer | Takeda Pharmaceutical Company |
| Dosage Forms | Intravenous injection |
| Medical Code | L01FX05 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01109025 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes